Vectura Announces Dry Powder Inhaler Capabilities Expansion at UK Facility

The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.

Vectura Group, an inhalation contract development and manufacturing organization, announced on March 9, 2021 that it will expand its dry powder inhaler (DPI) development and manufacturing capabilities at its facility in Chippenham, United Kingdom.

The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs, the company said in a press release. Additionally, the company will install a new capsule filler, a capsule blister packer, a Mikron semi-automated device assembly machine, and a semi-automated device assembly line as part of the expansion.

“Vectura has extensive specialist knowledge and experience in the development of dry powder inhalers, and this investment allows us to fully integrate these disciplines under one roof for pre-clinical, clinical, and commercial programs,” said Mark Bridgewater, chief commercial officer, in the press release. “The investment in new equipment will complement existing blister-based platform capabilities to offer customers greater flexibility, alongside our other inhalation delivery platforms, to provide patients with new inhaled therapies.”

Source: Vectura